What this deck covers
This deck focuses on Medication And Non Drug Therapy Selection, giving you a quick way to review the definitions, rules, and examples that matter most for NAPLEX.
Study Medication And Non Drug Therapy Selection in NAPLEX with focused flashcards that help you recognize the idea, recall the key rule, and apply it in practice-style prompts.
0% Complete
What medication class must be avoided in pregnancy due to fetotoxicity (renal failure, oligohydramnios)?
Tap card or press Space to flip
ACE inhibitors and ARBs. These inhibit the renin-angiotensin system, causing fetal renal damage, oligohydramnios, and other teratogenic effects during pregnancy.
How well did you know it?
Card 1 / 25
Space to flip · ← / → to move · once flipped, → Got it · ← Still learning
This deck focuses on Medication And Non Drug Therapy Selection, giving you a quick way to review the definitions, rules, and examples that matter most for NAPLEX.
Work through these flashcards in short sessions. Try to answer each prompt before flipping the card, then revisit any cards you miss until the explanation feels automatic.
Answer: ACE inhibitors and ARBs. These inhibit the renin-angiotensin system, causing fetal renal damage, oligohydramnios, and other teratogenic effects during pregnancy.
Answer: Bismuth quadruple therapy. This regimen uses bismuth and multiple antibiotics to eradicate H. pylori despite potential clarithromycin resistance.
Answer: Allopurinol. As a xanthine oxidase inhibitor, it reduces uric acid production to maintain low serum urate levels and prevent gout flares.
Answer: Varenicline. As a partial nicotinic agonist, it reduces cravings and withdrawal while blocking nicotine's rewarding effects.
Answer: Long-acting bronchodilator (LAMA or LABA). GOLD guidelines recommend long-acting bronchodilators for symptom relief in low-risk COPD patients without frequent exacerbations.
Answer: SSRI (or SNRI as an alternative first-line option). SSRIs enhance serotonin neurotransmission with a favorable efficacy and tolerability profile for depression treatment.
Answer: DOAC (apixaban, rivaroxaban, dabigatran, or edoxaban). DOACs provide effective stroke prevention with lower intracranial bleeding risk and no routine monitoring compared to warfarin.
Answer: Lithium, valproate, or an atypical antipsychotic. These mood stabilizers or antipsychotics rapidly control manic symptoms by modulating neurotransmitters and neuronal excitability.
Answer: Thiazide diuretic, ACE inhibitor, ARB, or dihydropyridine CCB. These classes are recommended by ACC/AHA guidelines as initial therapy due to proven efficacy in reducing cardiovascular events in uncomplicated hypertension.
Answer: Cognitive behavioral therapy for insomnia (CBT-I). CBT-I modifies maladaptive sleep behaviors and cognitions for sustained insomnia improvement without medication dependence.
Answer: Inhaled corticosteroid (ICS). GINA guidelines endorse ICS as they target airway inflammation, the key pathophysiology in persistent asthma.
Answer: SGLT2 inhibitor (if eGFR allows). SGLT2 inhibitors reduce heart failure hospitalizations and slow CKD progression via hemodynamic and anti-inflammatory effects.
Answer: Exercise, weight loss if overweight, and physical therapy. ACR guidelines prioritize these to strengthen muscles, reduce joint load, and improve function without pharmacologic side effects.
Answer: Duloxetine, pregabalin, gabapentin, or a TCA. These modulate central pain pathways, providing relief from neuropathic symptoms in diabetic neuropathy per guidelines.
Answer: Proton pump inhibitor (PPI). PPIs inhibit the proton pump to suppress acid secretion, promoting esophageal healing and symptom relief in GERD.
Answer: NSAID, colchicine, or systemic corticosteroid. These agents rapidly reduce inflammation and pain from monosodium urate crystal deposition in acute gout.
Answer: Metformin. ADA guidelines recommend it for improving insulin sensitivity and reducing hepatic glucose output with minimal hypoglycemia risk.
Answer: Nitrofurantoin, TMP-SMX, or fosfomycin. IDSA guidelines favor these for their efficacy against E. coli and low resistance in uncomplicated urinary tract infections.
Answer: Carvedilol, metoprolol succinate, or bisoprolol. These beta-blockers have demonstrated mortality reduction in large clinical trials for heart failure with reduced ejection fraction.
Answer: Warfarin. Warfarin is required for its adjustable anticoagulation in patients with mechanical valves to prevent thromboembolic complications.
Answer: Epinephrine intramuscularly. IM epinephrine rapidly activates alpha and beta receptors to reverse hypotension, bronchospasm, and angioedema in anaphylaxis.
Answer: GLP-1 receptor agonist or SGLT2 inhibitor with ASCVD benefit. These classes have evidence from CVOTs showing reduction in major adverse cardiovascular events in diabetic patients with ASCVD.
Answer: Fluoroquinolone (if local susceptibility is adequate). Fluoroquinolones provide broad gram-negative coverage and high renal concentrations for outpatient pyelonephritis treatment.
Answer: Antiplatelet therapy (aspirin or clopidogrel). Antiplatelets inhibit platelet aggregation to prevent recurrent atherothrombotic events post-stroke or TIA.
Answer: Tenofovir alafenamide (TAF) or entecavir. These nucleoside analogs inhibit HBV replication with lower risks of renal impairment or bone density loss compared to alternatives.